Michael D. Ezekowitz

Michael D. Ezekowitz's AcademicInfluence.com Rankings

Medical

#2297

World Rank

#2712

Historical Rank

Cardiology

#207

World Rank

#212

Historical Rank

medical Degrees

Michael D. Ezekowitz

Philosophy

#6692

World Rank

#9774

Historical Rank

Logic

#3821

World Rank

#5033

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Michael D. Ezekowitz's Degrees

Doctorate Medicine University of Pennsylvania
PhD Physiology University of Pennsylvania

Why Is Michael D. Ezekowitz Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael D. Ezekowitz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Dabigatran versus warfarin in patients with atrial fibrillation. (2009) (8312)
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. (2014) (5351)
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. (2014) (4138)
Edoxaban versus warfarin in patients with atrial fibrillation. (2013) (3988)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials (2014) (3577)
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. (2014) (2679)
Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association (2011) (2450)
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. (2014) (2287)
2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. (2012) (2260)
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. (2019) (1541)
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. (2001) (1507)
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. (2001) (1237)
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. (1992) (1151)
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial (2011) (1141)
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. (2019) (1088)
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task F (2012) (1046)
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial (2010) (1009)
2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2011) (1008)
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. (2019) (965)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (888)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (880)
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). (2014) (776)
The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study (2009) (751)
Newly identified events in the RE-LY trial. (2010) (739)
Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion (2010) (543)
Amiodarone versus sotalol for atrial fibrillation. (2005) (539)
Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. (2013) (493)
Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial (2013) (487)
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial (2010) (443)
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). (2007) (442)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2011) (426)
Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial (2012) (409)
Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial (2009) (389)
Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial (2012) (375)
Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy (2012) (367)
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. (2014) (365)
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. (2009) (363)
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study (2016) (359)
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis (2013) (346)
Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators (2009) (330)
Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry (2014) (325)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (321)
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design (2012) (319)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (317)
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial (2011) (310)
Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. (2011) (296)
Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation (2013) (284)
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin (2013) (282)
Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2013) (277)
Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. (1995) (256)
Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. (2006) (249)
Department of Veterans Affairs Cooperative Studies Program Clinical Trial Comparing Combined Warfarin and Aspirin With Aspirin Alone in Survivors of Acute Myocardial Infarction: Primary Results of the CHAMP Study (2002) (243)
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. (2012) (241)
Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial (2016) (223)
Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding (2013) (223)
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study (2013) (222)
Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial (2011) (219)
Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity A Scientific Statement From the American Heart Association (2018) (216)
Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study (2013) (216)
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure (2014) (199)
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. (2005) (197)
Effects of Atorvastatin on Stroke in Patients With Unstable Angina or Non-Q-Wave Myocardial Infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Substudy (2002) (193)
Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. (2015) (190)
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study (2016) (190)
Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation (2010) (189)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2011) (187)
ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Wr (2008) (174)
Incidence of Newly Detected Atrial Arrhythmias via Implantable Devices in Patients With a History of Thromboembolic Events (2010) (167)
Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention. (2012) (159)
International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD‐AF, ORBIT‐AF I, and ORBIT‐AF II registries (2017) (154)
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. (2014) (152)
Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. (2013) (140)
Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries: An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial (2012) (138)
Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II) (2018) (136)
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial (2018) (133)
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa) (2013) (123)
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. (2016) (119)
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. (2011) (118)
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. (2004) (113)
Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. (2003) (111)
Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (2013) (108)
Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry (2013) (106)
Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). (2013) (98)
Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options (2011) (98)
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). (2016) (97)
Gender in atrial fibrillation: Ten years later. (2010) (94)
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE‐LY trial (2011) (91)
Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. (1998) (88)
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score (2017) (85)
The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation (2009) (85)
Preventing stroke in patients with atrial fibrillation. (1999) (81)
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. (2016) (81)
Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). (2014) (80)
Peri-Procedural Bleeding and Thromboembolic Events with Dabigatran Compared to Warfarin: Results from the RE-LY Randomized Trial (2012) (80)
Electrocardiographic Early Repolarization: A Scientific Statement From the American Heart Association (2016) (79)
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation (2016) (78)
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. (2013) (78)
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. (2012) (75)
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. (2012) (75)
ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Wr (2008) (74)
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. (2015) (74)
Effects of dabigatran according to age in atrial fibrillation (2017) (74)
Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes (2015) (74)
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation (2020) (74)
Exercise Tolerance and Quality of Life in Elderly Patients with Chronic Atrial Fibrillation (2001) (70)
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. (2013) (67)
Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group. (1994) (66)
Atrial Fibrillation: The Epidemic of the New Millennium (1999) (65)
Re-Ly study of stroke prevention in atrial fibrillation Dabigatren versus warfarin in patients with atrial fibrillation N Engl J Med 2009; 361.10: 1056 (2009) (61)
Cardioversion of Atrial Fibrillation in ENGAGE AF‐TIMI 48 (2016) (60)
Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study (2017) (55)
Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). (2015) (55)
Diastolic dysfunction and atrial fibrillation (2008) (53)
Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? (2009) (52)
Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. (1995) (51)
Causes of Death and Influencing Factors in Patients With Atrial FibrillationClinical Perspective (2013) (50)
Role of transesophageal echocardiography in the detection of left atrial thrombus in patients with chronic nonrheumatic atrial fibrillation. (1995) (48)
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective (2016) (48)
Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. (2018) (48)
Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy (2014) (48)
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation (2017) (47)
D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy (2016) (46)
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. (2016) (44)
Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). (2003) (43)
Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. (2019) (43)
Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE‐LY trial (2015) (42)
The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. (2004) (42)
American Heart Association Atrial Fibrillation Research Summit: A Conference Report From the American Heart Association (2011) (41)
Growth‐differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long‐Term Anticoagulation Therapy (RE‐LY) trial (2017) (41)
The Impact of Patient Self-Testing of Prothrombin Time for Managing Anticoagulation: Rationale and Design of VA Cooperative Study #481—The Home INR Study (THINRS) (2005) (40)
Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex. (2022) (39)
Response to letter regarding article, "Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation". (2014) (39)
Isolated Drainage of the Superior Vena Cava into the Left Atrium in a 52-Year-Old Man (1978) (38)
INTERLEUKIN-6 AND C-REACTIVE PROTEIN AND RISK FOR DEATH AND CARDIOVASCULAR EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION (2011) (37)
Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial (2015) (36)
Use and Associated Risks of Concomitant Aspirin Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Insights from the ORBIT-AF Registry (2013) (36)
Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. (2016) (36)
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. (2015) (34)
Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures. (2016) (31)
Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring (1999) (30)
Epidemiology and management of new-onset atrial fibrillation. (2004) (29)
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) (2014) (28)
Review of Antiplatelet Therapy in Secondary Prevention of Cerebrovascular Events: A Need for Direct Comparisons Between Antiplatelet Agents (2005) (26)
Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. (2016) (26)
EFFECT OF AGE AND RENAL FUNCTION ON THE RISKS OF STROKE AND MAJOR BLEEDING WITH DABIGATRAN COMPARED TO WARFARIN: AN ANALYSIS FROM THE RE-LY STUDY (2010) (25)
Comparison of the effi cacy and safety of new oral anticoagulants with warfarin in patients with atrial fi brillation : a meta-analysis of randomised trials (2013) (25)
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation (2018) (24)
Double‐Blind Efficacy and Safet Study of a Novel Anti‐Ischemic Agent, Ranolazine, Versus Placebo in Patients With Chronic Stable Angina Pectoris (1994) (24)
Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE‐LY trial (2018) (23)
Efficacy and Safety of Dabigatran vs . Warfarin in Patients With Atrial Fibrillation – Sub-Analysis in Japanese Population in RELY Trial – (2011) (23)
Stroke Prevention in Atrial Fibrillation II Study. (1994) (23)
A randomized trial of budiodarone in paroxysmal atrial fibrillation (2012) (23)
Association Task Force on Practice Guidelines and the Heart Rhythm Society Executive Summary: A Report of the American College of Cardiology/American Heart 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: (2014) (22)
Anticoagulation in management of atrial fibrillation. (2003) (22)
Disease understanding in patients newly diagnosed with atrial fibrillation (2017) (22)
Anticoagulation management of valve replacement patients. (2002) (22)
COMPARISON OF DABIGATRAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION AND VALVULAR HEART DISEASE: THE RE-LY® TRIAL (2014) (22)
Contemporary management of atrial fibrillation. (1995) (21)
on Practice Guidelines of Cardiology Foundation Foundation/American Heart Association Task Force Atrial Fibrillation (Update on Dabigatran): A Report of the American College 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With (2011) (20)
Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. (2016) (20)
MANAGEMENT OF ARRHYTHMIAS (2000) (20)
Atrial fibrillation: modern concepts and management. (2005) (19)
Images in cardiovascular medicine. The case of a disappearing left atrial appendage thrombus: direct visualization of left atrial thrombus migration, captured by echocardiography, in a patient with atrial fibrillation, resulting in a stroke. (2006) (19)
Advancement in antithrombotics for stroke prevention in atrial fibrillation (2008) (19)
North American Thrombosis Forum, AF Action Initiative Consensus Document. (2016) (19)
Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial (2020) (19)
Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis (2019) (19)
The evolving field of stroke prevention in patients with atrial fibrillation. (2010) (18)
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. (2017) (18)
Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran (2018) (18)
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. (2016) (18)
Management and Outcomes of Major Bleeding On Dabigatran or Warfarin (2012) (18)
Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation (2018) (17)
Alternate-day dosing of aspirin in atrial fibrillation: A critical evaluation. (1999) (17)
Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. (2020) (17)
Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study (2018) (17)
Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score. (2015) (16)
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. (2016) (16)
Anticoagulation in management of atrial fibrillation (2003) (16)
Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society (2011) (16)
Physicians' Attitudes and the Use of Oral Anticoagulants: Surveying the Present and Envisioning Future (2003) (15)
Abstract 4629: Long-Term Open Label Extension of the Prevention of Embolic and Thrombotic Events on Dabigatran in Atrial Fibrillation (PETRO- Ex study) (2008) (15)
Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation (2020) (15)
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study (2017) (15)
DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION PATIENTS WITH LOW, MODERATE AND HIGH CHADS2 SCORE: A RE-LY SUBGROUP ANALYSIS (2010) (15)
Adding rigor to stroke risk prediction in atrial fibrillation. (2015) (15)
Asians and Non-Asians With Atrial Fibrillation Dabigatran Versus Warfarin : Effects on Ischemic and Hemorrhagic Strokes and Bleeding (2013) (15)
Maintaining sinus rhythm--making treatment better than the disease. (2007) (14)
Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. (2018) (14)
Atrial fibrillation: are there gender differences? (2000) (14)
Anticoagulation in the elderly. (2003) (14)
Warfarin therapy and systolic hypertension in men with atrial fibrillation. (2005) (14)
A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers (2015) (13)
Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). (2014) (13)
Anticoagulation interruptus: not without risk. (2004) (13)
Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease. (2004) (13)
Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial (2019) (12)
Dabigatran etexilate and reduction in serum apolipoprotein B (2015) (12)
Neuroprotective effects of statins may not be related to total and low-density lipoprotein cholesterol lowering. (2002) (12)
New developments in anticoagulation for atrial fibrillation (2008) (11)
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation (2021) (11)
Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials (2020) (11)
Shared Decision Making in Atrial Fibrillation: Patient-Reported Involvement in Treatment Decisions. (2020) (11)
Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). (2019) (10)
The World of Pacing and Electropysiology: Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation (2001) (10)
Practice Guidelines College of Cardiology Foundation/American Heart Association Task Force on Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With (2011) (10)
Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation (2020) (10)
Dabigatran in atrial fibrillation: pharmacology and clinical trials (2011) (10)
Executive Summary: Pivotal Research in Cardiovascular Syndromes in the Elderly. (2000) (9)
Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE‐LY trial analysis (2018) (9)
Abstract 18321: D-dimer is Prognostic for Stroke, Major Bleeding and Death During Anticoagulation of Atrial Fibrillation - a RELY Substudy (2010) (9)
Atrial fibrillation: outpatient presentation and management. (2011) (9)
Management of dyspepsia symptoms on dabigatran during RELY-ABLE : long-term follow up study after RE-LY (2013) (9)
The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE‐AF) study (2017) (9)
Atorvastatin for acute coronary syndromes. (2001) (9)
Double-blind, placebo-controlled trial of propranolol given once, twice and four times daily in stable angina pectoris: a multicenter study using serial exercise testing. (1984) (9)
Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry (2018) (9)
Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. (2019) (9)
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. (2019) (8)
Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation (2001) (8)
Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial. (2001) (8)
The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Trial: Effects of Intensive Atorvastatin Treatment on Early Recurrent Events After an Acute Coronary Syndrome (2000) (8)
Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years : Results of the Rely-Able Double-Blind Randomized Trial (2012) (8)
Secondary prevention in concurrent coronary artery, cerebrovascular, and chronic kidney disease: focus on pharmacological therapy. (2009) (8)
AHA Policy Statement Forecasting the Future of Cardiovascular Disease in the United States A Policy Statement From the American Heart Association (2011) (8)
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. (2019) (7)
Abstract 9174: Global Variation in the Etiology and Management of Atrial Fibrillation: Results from a Global Atrial Fibrillation Registry (2011) (7)
Vasoactive intestinal polypeptide in cardiac myxoma. (1985) (7)
Abstract 15537: Dabigatran Versus Warfarin in Very Elderly Patients with Atrial Fibrillation: Results from the RE-LY Trial (2012) (7)
Warfarin and antiplatelet therapy study in chronic heart failure (WATCH): Trial design (1999) (7)
Differences in Thromboembolic Complications Between Paroxysmal and Persistent Atrial Fibrillation Patients Following Electrical Cardioversion (From the ENSURE-AF Study). (2020) (7)
Efficacy and Safety of Dabigatran Compared with Warfarin in Relation to Baseline Renal Function in Patients with Atrial Fibrillation: A RE-LY Trial Analysis (2013) (7)
The Management of Patients with Atrial Fibrillation (1997) (6)
Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas (2021) (6)
Novel Anticoagulants Eliminate the Need for Left Atrial Appendage Exclusion Devices (2014) (6)
GUIDELINE 2011 ACCF / AHA / HRS Focused Update on the Management of Patients With Atrial Fibrillation ( Updating the 2006 Guideline ) (2010) (6)
Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic (2021) (5)
Abstract 15020: A Placebo-Controlled, Double-Blind, Randomized, Multicenter Study to Assess the Effects of Dronedarone on Atrial Fibrillation Burden in Subjects with Permanent Pacemakers (HESTIA) (2012) (5)
Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. (2019) (5)
DABIGATRAN VERSUS WARFARIN AND IMPACT OF CHAD2-VASC SCORE ON OUTCOME IN ATRIAL FIBRILLATION PATIENTS: A RE-LY SUBGROUP ANALYSIS (2011) (5)
Drug Interactions Affecting Oral Anticoagulant Use (2022) (5)
Efficacy and Safety of Dabigatran Versus Warfarin in Patients with Atrial Fibrillation : Analysis in Asian Population in RE-LY Trial (2012) (5)
Clinical implication of antiembolic trials in atrial fibrillation and role of transesophageal echocardiography in atrial fibrillation. (2000) (5)
Sunday, 26 August 2012 (2012) (5)
Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). (2021) (5)
Abstract 12862: Predictors of Hospitalization and Effects of Dabigatran and Warfarin on Hospitalization Rates: An Analysis From The Re-ly Trial (2015) (5)
DABIGATRAN ETEXILATE VERSUS WARFARIN IN PATIENTS WITH DIFFERENT TYPES OF ATRIAL FIBRILLATION: A RE-LY® SUBGROUP ANALYSIS (2011) (5)
Prevention of thromboembolism in patients with atrial fibrillation. (1996) (5)
Reducing stroke rates in patients with atrial fibrillation: how low can we go? (2009) (5)
on behalf of the RE-LY Atrial Fibrillation Registry Investigators (2014) (4)
The impact of IMPACT-AF (2017) (4)
Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study". (2014) (4)
Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. (2021) (4)
Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties. (2005) (4)
Abstract 12492: Cystatin C is Prognostic for Stroke, Death and Bleeding in Atrial Fibrillation - A RELY Substudy (2011) (4)
Reply: regarding the effect of dabigatran plasma concentrations. (2014) (4)
Abstract 14808: Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation - A RELY Substudy (2012) (4)
The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic (2021) (4)
Abstract 13472: NT-proBNP is Prognostic for Stroke and Death in Atrial Fibrillation - a RELY Substudy (2010) (3)
Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged ≥80 years With Atrial Fibrillation. (2021) (3)
Does dabigatran improve stroke‐prevention in atrial fibrillation? Reply to a rebuttal (2010) (3)
Patterns of oral anticoagulation use with cardioversion in clinical practice (2020) (3)
Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials (2020) (3)
LVS‐HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World‐Wide Registry (2021) (3)
Monday, 27 August 2012 (2012) (3)
Combination Hemotherapy and Mortality Prevention (CHAMP) Study Rationale and Design (1998) (3)
Chronic antithrombotic therapy in post-myocardial infarction patients. (2006) (3)
Chronic antithrombotic therapy in post-myocardial infarction patients. (2008) (3)
Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial (2015) (3)
Central Clinical Research Issues in Electrophysiology: Report of the NASPE Committee (2001) (3)
Atrial Fibrillation (Updating the 2006 Guideline) 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With (2011) (3)
Approach to management of the patient over age 75 with atrial fibrillation. (2000) (3)
Abstract 11087: Benefits of Dabigatran versus Warfarin in Hypertensive Patients With Atrial Fibrillation: Results From The Re-ly Trial (2013) (2)
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation (2020) (2)
Efficacy and Safety of Dabigatran Etexilate vs . Warfarin in Asian RELY Patients According to Baseline Renal Function or CHADS 2 Score (2015) (2)
5770A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials (2017) (2)
Atrial Fibrillation (Update on Dabigatran) 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With (2011) (2)
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial (2014) (2)
RE-LY and RELY-ABLE : Long-term Follow-up of Patients With Non-valvular Atrial Fibrillation Receiving Dabigatran Etexilate for Up to 6.7 Years (2013) (2)
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: reply to a rebuttal (2012) (2)
Abstract 12041: The Risk of Peri-Operative Bleeding with Warfarin Compared to Two Doses of Dabigatran: Results From the RE-LY Trial (2011) (2)
Abstract WP403: Factors Associated With Patient-Reported Shared Decision-Making for Stroke Prevention in Atrial Fibrillation (2019) (2)
Reply: Anticoagulant-Related Nephropathy. (2015) (2)
Mo1999 How Often Does Major Gastrointestinal Bleeding in Patients Receiving Warfarin or Dabigatran Uncover Cancer? The U.S. Experience From the RELY Trial (2015) (2)
Left Ventricular Thrombi: Uncommon But Clinically Important. (2020) (2)
EFFECT OF DABIGATRAN ON SERUM APOLIPOPROTEIN B AND APOLIPOPROTEIN A1 CONCENTRATIONS (2013) (2)
CLINICAL OUTCOMES OF ATRIAL FIBRILLATION PATIENTS RECEIVING DIGOXIN IN THE RE-LY® TRIAL (2016) (2)
EXTERNAL VALIDATION OF THE BIOMARKER-BASED ABC-BLEEDING RISK SCORE FOR ATRIAL FIBRILLATION (2016) (2)
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants—translating clinical trial data into practice (2014) (2)
Anticoagulation Therapy for Atrial Fibrillation and Coronary Disease (2000) (1)
STROKE RISK PREDICTION IN PATIENTS WITH ATRIAL FIBRILLATION AND RHEUMATIC HEART DISEASE: RESULTS FROM THE RE-LY AF REGISTRY (2019) (1)
Abstract 15740: Concomitant Use of Dronedarone and Direct Oral Anticoagulants and Risk of Bleeding in Patients With Atrial Fibrillation: An Analysis of the U.S. Truven Health MarketScan Database (2020) (1)
Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation : insights from the RE-LY trial (2016) (1)
Statement From the American Heart Association Forecasting the Future of Cardiovascular Disease in the United States: A Policy (2011) (1)
With Atrial Fibrillation (RELY-ABLE) Study The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients (2013) (1)
Patients With Atrial Fibrillation: Switching Emphasis From Stroke Prevention to Stroke and Hemorrhage Prevention. (2017) (1)
A meta-analysis of risks versus benefit of oral anticoagulation on top of aspirin following unstable angina or myocardial infarction (2002) (1)
CHA2DS2-VASC VERSUS HAS-BLED SCORE FOR PREDICTING RISK OF MAJOR BLEEDING AND ISCHEMIC STROKE IN ATRIAL FIBRILLATION: INSIGHTS FROM RE-LY TRIAL (2016) (1)
Recurrent Events and Mortality Among Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the RE-LY Trial (2013) (1)
Prevention of Stroke. (1998) (1)
Principles of Anticoagulation and New Therapeutic Agents in Atrial Fibrillation. (2010) (1)
Pharmacological Control of Rate and Maintenance of Sinus Rhythm (2004) (1)
Medical prevention of secondary stroke: A cardiologist's perspective (2004) (1)
Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation (2022) (1)
Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study (2020) (1)
Abstract 4415: The Utility of Genotyping in the First Evaluation of a Novel Vitamin K Antagonist: ATI-5923 (2008) (1)
Stroke prevention in atrial fibrillation: anticoagulants and antithrombotics. (2004) (1)
Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin". (2014) (1)
Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trial. (2021) (1)
Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy". (2013) (1)
EFFECTS OF DABIGATRAN VERSUS WARFARIN IN RELATION TO LEFT VENTRICULAR HYPERTROPHY IN ATRIAL FIBRILLATION (2016) (1)
Letter regarding article by Connolly et al, "Challenges of establishing new antithrombotic therapies in atrial fibrillation". (2008) (1)
Abstract 16785: Atrial Fibrillation Clinical Phenotypes: A Cluster Analysis (2017) (1)
Management of arrythmias. (2000) (1)
1117-88 High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: Results from the MIRACL trial (2004) (0)
Cardiac Pacing And Electrophysiology International Calendar of Events (2004) (0)
·P-72 A crossover analysis of the educational benefits of a patient information handbook (1990) (0)
Clinician Update Atrial Fibrillation Outpatient Presentation and Management (2011) (0)
The Role of Newer Anticoagulants in the Treatment of Atrial Fibrillation (2010) (0)
A RETROSPECTIVE ANALYSIS OF ATRIAL FIBRILLATION PATIENTS AGED 80 YEARS AND OLDER PRESCRIBED WARFARIN OR A LOW-DOSE DIRECT ORAL ACTING ANTICOAGULANT (2021) (0)
EDOXABAN THERAPY INCREASES TREATMENT SATISFACTION AND REDUCES UTILIZATION OF HEALTH CARE RESOURCES: AN ANALYSIS FROM THE EDOXABAN VERSUS WARFARIN IN SUBJECTS UNDERGOING CARDIOVERSION OF ATRIAL FIBRILLATION (ENSURE-AF) STUDY (2017) (0)
Genetic determinants of warfarin response, efficacy and safety : a RE-LY genomics substudy (2012) (0)
Abstract 210: Stroke-Related Specific Mortality and Influencing Factors in Patients with Atrial Fibrillation in the RE-LY Trial (2013) (0)
Mortality after the hospitalization of a spouse. (2006) (0)
Controversies in clinical care: Who should receive anticoagulatiuon therapy for atrial fibrillation ? (2002) (0)
CHARACTERISTICS OF AF PATIENTS WITH LARGE IMPROVEMENT IN SYMPTOMS AT ONE YEAR: SUPER-RESPONSE IN THE ORBIT-AF REGISTRY (2019) (0)
D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy (2016) (0)
Abstract 19349: Blood Pressure Control in Community Dwelling Patients with Atrial Fibrillation: Results from the ORBIT-AF Registry (2014) (0)
The combination of warfarin and aspirin reduced the rate of IHD events more effectively than either agent alone. (1998) (0)
Abstract 10: Contraindications to Oral Anticoagulation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) (2013) (0)
794 What is the Clinical Profile of “Life-Threatening” Gastrointestinal Bleeding in Anticoagulated Patients? A Sub-Analysis of the RE-LY Trial (2016) (0)
Abstract P131: Importance of Algorithm-Consistent Warfarin Dosing in the Quality of Anticoagulation Control in Atrial Fibrillation: A Multilevel Analysis (2011) (0)
P6365Clinical predictors of left atrium thrombi in patients scheduled for cardioversion of atrial fibrillation: a subanalysis from the ENSURE-AF study (2017) (0)
Stroke reduction with low-medium dose warfarin/ aspirin combination following myocardial infarction in the CHAMP study (2002) (0)
Atrial fibrillation in the elderly (1998) (0)
Auto-immune haemolytic anaemia and paroxysmal nocturnal haemoglobinuria red cell abnormality in the same patient. (1974) (0)
ASSOCIATION BETWEEN GUIDELINE-DIRECTED MEDICAL THERAPIES FOR COMORBID CONDITIONS AND CLINICAL OUTCOMES AMONG INDIVIDUALS WITH ATRIAL FIBRILLATION (2019) (0)
CARDIOVERSIONS AND ATRIAL FIBRILLATION: PATIENT OUTCOMES IN THE UNITED STATES: DATA FROM ORBIT-AF (2014) (0)
University of Birmingham Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion (2018) (0)
Clinical Outcomes of Patients with Previous Transient Ischaemic Attack or Stroke - a Subgroup Analysis of the Long-Term Extension of Dabigatran in Patients with Atrial Fibrillation (RELY-ABLE) Study (2013) (0)
Quality of Life and Exercise Performance in Patients in Sinus Rhythm Versus Persistent Atrial Fibrillation A Cooperative Studies Program Substudy (2006) (0)
Bleeding and thromboembolic outcomes in warfarin-and dabigatran-treated patients in the RE-LY trial who required an urgent surgery or procedure (2015) (0)
Journal Pre-proof Residual Stroke Risk Despite Oral Anticoagulation in Patients with Atrial Fibrillation (2022) (0)
Abstract 13006: High Use of Concomitant Antiplatelet Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Results from the ORBIT-AF Registry (2012) (0)
Abstract 18466: Anemia is Associated with an Adverse Outcome in Patients with Atrial Fibrillation: Insights Form the Re-ly Trial (2012) (0)
Abstract 057: Understanding of Treatment Strategies Among Patients Newly Diagnosed With Atrial Fibrillation: Findings From SATELITTE (2017) (0)
Abstract 19504: Factors Predicting Sinus Rhythm in Patients Cardioverted in the X-VERT Study (2014) (0)
Abstract P220: Interim Results of the Registry to Evaluate Anticoagulation in Atrial Fibrillation (REAL-AF) (2011) (0)
TCT-190 Dabigatran versus Warfarin for stroke prevention in Patients with Atrial Fibrillation: A Post-Hoc Analysis of RE-LY Correlating Body Mass Index with Outcome According to BMI Quintiles (2017) (0)
Applying antithrombotic therapies to improve outcomes in patients with atrial fibrillation. (2013) (0)
Abstract 2756: Time Dependent Efficacy of Budiodarone, an Analog of Amiodarone, in Patients With Paroxysmal AF and Implantable Pacemaker Capable of Monitoring Rhythm (2009) (0)
ASSOCIATION BETWEEN ELEVATED B-TYPE NATRIURETIC PEPTIDE, DISEASE PROGRESSION, AND CLINICAL OUTCOMES AMONG PATIENTS WITH ATRIAL FIBRILLATION (2018) (0)
Response to Letter Regarding Article, “Atrial Fibrillation: Outpatient Presentation and Management” (2012) (0)
NON VITAMIN K ORAL ANTICOAGULANTS ARE NOT ASSOCIATED WITH INCREASED RISK OF PERIOPERATIVE BLEEDING IN PATIENTS UNDERGOING CARDIAC SURGERY (2019) (0)
Randomized trials of aspirin and anticoagulant therapy in atrial fibrillation (1999) (0)
Poster Session 4: ECG (2009) (0)
Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis". (2014) (0)
Trial Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Quality of Anticoagulation Control Between Centers and Countries : An Analysis of Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the (2012) (0)
SELECTION OF RATE VERSUS RHYTHM CONTROL FOR TREATMENT OF ATRIAL FIBRILLATION IN CLINICAL PRACTICE: RESULTS FROM THE ORBIT-AF REGISTRY (2012) (0)
Overestimation of anticoagulant benefit in patients with atrial fibrillation and low life expectancy: evidence from 12 randomized trials (2023) (0)
Anticoagulation in Atrial Arrhythmias (2012) (0)
Upper Gastrointestinal Symptoms Related to Dabigatran. An Analysis of the RE-LY Trial with 18,113 Subjects: 94 (2011) (0)
South Africa revisited--lessons to be learned from mistakes in American health care policy. (1991) (0)
Abstract 19757: Comparison of Contemporary Bleeding Risk Scores in Patients With Non-Valvular Atrial Fibrillation Treated With Dabigatran or Warfarin: Insights From the RE-LY Trial (2016) (0)
Abstract 13111: The Registry to Evaluate Anticoagulation in Atrial Fibrillation (REAL-AF) (2010) (0)
The effects of amiodarone versus sotalol versus placebo on quality of life measurements and exercise duration in patients with persistent atrial fibrillation (2003) (0)
Health Care Cost In Patients Undergoing Electrical Cardioversion: An analysis from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ensure-af) study (2017) (0)
TCT-62 Impact of Atrial Fibrillation in Patients with STEMI Before and After Primary PCI: Insights from the HORIZONS-AMI Trial (2012) (0)
BLOOD PRESSURE AND RISK FOR STROKE OR BLEEDING EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS FROM THE ORBIT AF STUDY (2015) (0)
Aha Conference Proceedings American Heart Association Atrial Fibrillation Research Summit a Conference Report from the American Heart Association Mechanisms of Af: Basic and Translational Science and Genetics (2011) (0)
JACC March 6, 2 0 0 2 1171-30 A Meta-Analysie of Risks Versus Benefit of Oral Antlcoagulation on Top of Aspirin Following Unstable Angina or Myocardial Infarction (2016) (0)
Response to Letter by Willey (2010) (0)
Abstract 15084: A Retrospective Analysis of Atrial Fibrillation Patients Aged 80 Years and Older Prescribed a Low-dose Non-vitamin K Antagonist Anticoagulant (2020) (0)
Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant (2022) (0)
NUISANCE BLEEDING IN ANTICOAGULATED PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT OF ATRIAL FIBRILLATION (ORBIT-AF) (2017) (0)
Erratum to: A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers (2015) (0)
Stroke prevention in atrial fibrillation (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael D. Ezekowitz?

Michael D. Ezekowitz is affiliated with the following schools:

Michael D. Ezekowitz's Academic­Influence.com Rankings

Michael D. Ezekowitz's Degrees

Why Is Michael D. Ezekowitz Influential?

Michael D. Ezekowitz's Published Works

Published Works

What Schools Are Affiliated With Michael D. Ezekowitz?

Michael D. Ezekowitz's AcademicInfluence.com Rankings